Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- TOPICS／Cervarix Wins Tender for UK National Immunization Program: GSK
August 4, 2008
- Alizyme Licenses COLAL-PRED to Norgine in Europe
August 4, 2008
- BMS, AZ Apply for Saxagliptin in Europe
August 4, 2008
- BUSINESS NEWS IN BRIEF
August 4, 2008
- Primovist Approved in the US: Bayer HealthCare
August 4, 2008
- TOPICS／JADEC, sanofi-aventis Cosponsor HbA1c Awareness Enhancement Campaign
August 4, 2008
- PMDA Receives Highest Rating Regarding Balance of Payment, Relief of ADR Victims
August 4, 2008
- NEW PRODUCTS／Aroglycem Cap. for Hypoglycemia due to Hyperinsulinemia: Schering-Plough
August 4, 2008
- OPINION／Who Makes \30 Million? Our Survey Reveals All
August 4, 2008
- Irinotecan to See First Generics in November
August 4, 2008
- Kobayashi Launches 7 New Products
August 4, 2008
- Councils for Promotion of Use of Generics Created by 30 Prefectures
August 4, 2008
- Paltac KS to Report Profits This Fiscal Year
August 4, 2008
- More Doctors Concerned about Quality of Generics Based on Their Own Experience
August 4, 2008
- Miconazole, Emedastine Fumarate Classified into Class 1 OTC Drugs
August 4, 2008
- GENERICS NEWS IN BRIEF
August 4, 2008
- Updating Reduces Number of Class 1 OTC Drugs from 23 to 21
August 4, 2008
- Fuji Yakuhin Developing Drug for Gout at PII
August 4, 2008
- SELF-MEDICATION NEWS IN BRIEF
August 4, 2008
- Novartis to Apply for Everolimus for RCC within 2008
August 4, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…